Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Mojca Maticic"'
Autor:
Loreta A. Kondili, Maria Buti, Mar Riveiro-Barciela, Mojca Maticic, Francesco Negro, Thomas Berg, Antonio Craxì
Publikováno v:
JHEP Reports, Vol 4, Iss 9, Pp 100531- (2022)
Background & Aims: The World Health Organization (WHO) HBV and HCV elimination targets, set in 2016 and based on projections to 2030, were unable to consider the impact of intervening factors. To evaluate the impact of the COVID-19 pandemic on viral
Externí odkaz:
https://doaj.org/article/e1975131ea34424cb8118f3313dde5ce
Publikováno v:
Zdravniški Vestnik, Vol 89, Iss 11-12, Pp 702-709 (2020)
In response to neighbouring Italy’s accelerating outbreak of the coronavirus disease 2019 (COVID-19), Slovenia established a national toll-free telephone helpline, which operated from 9 March until 12 June 2020 and answered more than 40 thousand ca
Externí odkaz:
https://doaj.org/article/57199afd63b5471dae590801fde7488c
Autor:
Katherine C Sharrock, Teymur Noori, Maria Axelsson, Maria Buti, Asuncion Diaz, Olga Fursa, Greet Hendrickx, Cary James, Irena Klavs, Marko Korenjak, Mojca Maticic, Antons Mozalevskis, Lars Peters, Rafaela Rigoni, Magdalena Rosinska, Kristi Ruutel, Eberhard Schatz, Thomas Seyler, Irene Veldhuijzen, Erika Duffell
Publikováno v:
PLOS Global Public Health, Vol 2, Iss 8, p e0000841 (2022)
This paper presents data on selected indicators to show progress towards elimination goals and targets for hepatitis B and hepatitis C in the 31 countries of the European Union (EU) and European Economic Area (EEA). A monitoring system was developed
Externí odkaz:
https://doaj.org/article/1d666b1317494b2788db65665461d97e
Autor:
Mojca Maticic, Jerneja Videcnik Zorman, Sergeja Gregorcic, Eberhard Schatz, Jeffrey V. Lazarus
Publikováno v:
Harm Reduction Journal, Vol 16, Iss 1, Pp 1-13 (2019)
Abstract Background Hepatitis C virus (HCV) infection is the leading cause of cirrhosis, end-stage liver disease and hepatocellular carcinoma (HCC) worldwide. In Europe, people who inject drugs (PWID) represent the majority of HCV infections, but are
Externí odkaz:
https://doaj.org/article/924233f2dd694599b6b8e50bb4d29f66
Autor:
Tobias Boettler, Thomas Marjot, Philip N. Newsome, Mario U. Mondelli, Mojca Maticic, Elisa Cordero, Rajiv Jalan, Richard Moreau, Markus Cornberg, Thomas Berg
Publikováno v:
JHEP Reports, Vol 2, Iss 5, Pp 100169- (2020)
Summary: During the early stages of the coronavirus disease 2019 (COVID-19) pandemic, EASL and ESCMID published a position paper to provide guidance for physicians involved in the care of patients with chronic liver disease. While some healthcare sys
Externí odkaz:
https://doaj.org/article/8716cf90b2664374a5fef1ec254be647
Autor:
Tobias Boettler, Philip N. Newsome, Mario U. Mondelli, Mojca Maticic, Elisa Cordero, Markus Cornberg, Thomas Berg
Publikováno v:
JHEP Reports, Vol 2, Iss 3, Pp - (2020)
Summary: The coronavirus disease 2019 (COVID-19) pandemic poses an enormous challenge to healthcare systems in affected communities. Older patients and those with pre-existing medical conditions have been identified as populations at risk of a severe
Externí odkaz:
https://doaj.org/article/3c0b91a5b330433bae149895cdca9203
Autor:
Adam Palayew, Samya R Stumo, Graham S Cooke, Sharon J Hutchinson, Marie Jauffret-Roustide, Mojca Maticic, Magdalena Harris, Ammal M Metwally, Homie Razavi, Jeffrey V Lazarus, Hep-CORE Study Group
Publikováno v:
PLoS ONE, Vol 15, Iss 7, p e0235715 (2020)
BackgroundNew hepatitis C virus (HCV) treatments spurred the World Health Organization (WHO) in 2016 to adopt a strategy to eliminate HCV as a public health threat by 2030. To achieve this, key policies must be implemented. In the absence of monitori
Externí odkaz:
https://doaj.org/article/319704c7b5bb41fc9f466a4a4cedfc5b
Introduction and utilisation of high priced HCV medicines across Europe; implications for the future
Autor:
Winnie de Bruijn, Cristina Ibáñez, Pia Frisk, Hanne Bak Pedersen, Ali Alkan, Patricia Vella Bonanno, Ljiljana Sović Brkičić, Anna Bucsics, Guillame Dedet, Jaran Eriksen, Joseph O Fadare, Jurij Fürst, Gisselle Gallego, Isabella Piassi Godói, Augusto Afonso Guerra Junior, Hakki Gürsöz, Saira Jan, Jan Jones, Saim Kerman, Roberta Joppi, Ott Laius, Newman Madzikwa, Einar Magnusson, Mojca Maticic, Vanda Markovic-Pekovic, Amos Massele, Olayinka Ogunleye, Aisling O’Leary, Jutta Piessnegger, Catherine Sermet, Steven Simoens, Celda Tiroyakgosi, Ilse Truter, Magnus Thyberg, Kristina Tomekova, Magdalene Wladysiuk, Sortiris Vandoros, Elif Hilal Vural, Corinne Zara, Brian Godman
Publikováno v:
Frontiers in Pharmacology, Vol 7 (2016)
Background: Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines to treat HCV infection grew 2.7% per year between 20
Externí odkaz:
https://doaj.org/article/442ad35f14564b47bc0809c09511b491
Autor:
Heiner Wedemeyer, Tammo L. Tergast, Jeffrey V. Lazarus, Homie Razavi, Kostas Bakoyannis, Ricardo Baptista‐Leite, Marco Bartoli, Philip Bruggmann, Cristian‐Silviu Buşoi, Maria Buti, Manuel Carballo, Laurent Castera, Massimo Colombo, Rodrigo Sousa Coutinho, Yuval Dadon, Gamal Esmat, Rafael Esteban, Joan Colom Farran, Mark Gillyon‐Powell, David Goldberg, Sharon Hutchinson, Harry L. A. Janssen, George Kalamitsis, Loreta A. Kondili, John S. Lambert, Rui Tato Marinho, Mojca Maticic, Aldo Patricello, Markus Peck‐Radosavljevic, Stanislas Pol, Mario Poljak, Cora Pop, Tomislov Sokol, Vana Sypsa, Nurdan Tözün, Zobair Younossi, Alessio Aghemo, George V. Papatheodoridis, Angelos Hatzakis
Publikováno v:
Liver International. 43(2):276-291
In 2016, the Hepatitis B and C Public Policy Association (HepBCPPA), gathered all the main stakeholders in the field of hepatitis C virus (HCV) to launch the now landmark HCV Elimination Manifesto, calling for the elimination of HCV in the EU by 2030
Autor:
Maria Buti, Antonio Craxi, Graham R. Foster, Mojca Maticic, Francesco Negro, Stefan Zeuzem, Fabien Zoulim
Publikováno v:
Journal of Hepatology. 77:1444-1447
Advances in diagnostics and therapeutics have brought the elimination of chronic viral hepatitis into focus. The World Health Organization has defined the targets for elimination, but it is unclear how these can be achieved and how they should be mea